menu
    • menu
    [{"orgOrder":0,"company":"Wugen","sponsor":"Alpha Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Memory NK Therapy","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Wugen \/ Alpha Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Wugen \/ Alpha Biopharma"},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"WU-CART-007","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Not Applicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"WU-NK-101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Not Applicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"WU-NK-101","moa":"KIR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Not Applicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"WU-CART-007","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Not Applicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Not Applicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Not Applicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic CAR-T Cell","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Not Applicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"WU-NK-101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Not Applicable"},{"orgOrder":0,"company":"Wugen","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"WU-CART-007","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Wugen","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Wugen"},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"WU-CART-007","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Wugen \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Wugen

    Menu

    Wugen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WU-CART-007

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wugen to Initiate Pivotal Trial for WU-CART-007 in T-ALL/LBL

                            Details : WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy, engineered to treat relapsed or refractory T cell acute lymphoblastic leukemia or lymphoma.

                            Brand Name : WU-CART-007

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 12, 2024

                            Lead Product(s) : WU-CART-007

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WU-CART-007

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MaxCyte and Wugen Sign License to Expedite Manufacturing of Cell Therapies for Cancer

                            Details : Wugen gains non-exclusive clinical and commercial rights to MaxCyte’s Flow Electroporation® technology to support programs like WU-CART-007 for hematologic and solid tumors.

                            Brand Name : WU-CART-007

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 30, 2024

                            Lead Product(s) : WU-CART-007

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WU-NK-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK...

                            Details : WU-NK-101 is a cytokine-reprogrammed, expanded, cryopreserved, off-the-shelf NK cell product, investigated to treat patients with relapsed or refractory acute myeloid leukemia.

                            Brand Name : WU-NK-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 15, 2023

                            Lead Product(s) : WU-NK-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic CAR-T Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress

                            Details : WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies.

                            Brand Name : WU-CART-007

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 11, 2023

                            Lead Product(s) : Allogeneic CAR-T Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WU-NK-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncolog...

                            Details : WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic function.

                            Brand Name : WU-NK-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 10, 2022

                            Lead Product(s) : WU-NK-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WU-NK-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO)...

                            Details : WU-NK-101’s unique cytokine-induced memory-like phenotype and support its clinical development for solid tumors,including its potent anti-tumor cytotoxicity and enhanced metabolic fitness that supports resilience within immunosuppressive solid TME.

                            Brand Name : WU-NK-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 04, 2022

                            Lead Product(s) : WU-NK-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WU-CART-007

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wugen Receives U.S. FDA Fast Track and Rare Pediatric Disease Designations for WU-CART-007 for the Treatment o...

                            Details : WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies.

                            Brand Name : WU-CART-007

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 19, 2022

                            Lead Product(s) : WU-CART-007

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WU-NK-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wugen to Present Preclinical Data on WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congre...

                            Details : The data highlight preclinical activity of WU-NK-101 supporting its clinical development for acute myeloid leukemia (AML). WU-NK-101 displayed activity against AML cell lines both in vitro and in vivo, and improved homing to the bone marrow.

                            Brand Name : WU-NK-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 12, 2022

                            Lead Product(s) : WU-NK-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WU-NK-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wugen to Present at the Innate Killer Summit 2022

                            Details : WU-NK-101, novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors, is currently in development for acute myelogenous leukemia (AML) and solid tumors.

                            Brand Name : WU-NK-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 24, 2022

                            Lead Product(s) : WU-NK-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Wugen

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WU-CART-007

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/R T...

                            Details : WU-CART-007 is an off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies.

                            Brand Name : WU-CART-007

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 15, 2022

                            Lead Product(s) : WU-CART-007

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth